Rimonabant Clinical Study
Patients treated for one year with rimonabant
20 mg per day lost 8.6 kg (almost 20 lbs.) vs. a loss of only 2.3
kg (5 lbs.) on placebo (p<0.001). Nearly 75% (p<0.001 vs.
placebo) of patients treated for one year with ACOMPLIA(TM) 20 mg
lost over 5% of their body weight as compared to 41.8% (p = 0.002
vs. placebo) of patients on ACOMPLIA(TM) 5 mg and 27.6% of patients
in the placebo group. Moreover, 44.3% (p<0.001 vs. placebo) lost
more than 10% of their body weight when treated for one year with
ACOMPLIA(TM) 20 mg vs. 16.3% of patients on ACOMPLIA(TM) 5 mg or
10.3% of patients on placebo. In addition to weight loss, RIO-Lipids
was designed to assess a number of associated important cardiovascular
risk factors. All improvements in risk factors were statistically
significant vs. the control group. In fact, the number of patients
diagnosed as having metabolic syndrome1 at baseline (52.9%) was
reduced by half (25.8%) after treatment with ACOMPLIA(TM) 20 mg
(p<0.0001 compared to placebo). Study findings for rimonabant
20 mg include:
Waist circumference reduction of 9.1 cm (3.5 inches)
in patients treated for a year (completers) with rimonabant 20 mg
(p<0.001 vs. placebo).
Average increase of 23% in HDL-cholesterol in completers
(p<0.001 vs. placebo).
Average reduction of 15% in triglycerides in completers
(p<0.001 vs. placebo).
A positive shift in LDL particle size, with a reduction
(p=0.002 vs. placebo) in the proportion of smaller dense atherogenic
LDL particles, which are associated with cardiovascular risk, and
an increase (p<0.001 vs. placebo) in the proportion of larger,
less atherogenic LDL particles.
|
